TG Therapeutics (TGTX) Misses Q2 Earnings Estimates
TG Therapeutics (TGTX) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.04 per share a year ago.
TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q2 Release
TG Therapeutics (TGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TG Therapeutics: Another Possible Avenue Of MS Growth With Azer-Cel
TG Therapeutics, Inc.'s BRIUMVI saw Q1 2025 revenue surge 137% YoY to $119.7M, driven by strong U.S. growth. A subcutaneous version of TGTX's BRIUMVI is in phase 1 trials, with late-stage development planned for 2025, aiming to broaden patient reach and administration options. Azer-cel, an allogeneic off-the-shelf CD19 CAR-T, is in phase 1 for progressive MS, targeting a new MS market segment beyond relapsing MS.
TG Therapeutics: Estimates Could Soon Be Raised Again
TG Therapeutics remains on track, with Q1 revenue matching my model and potential for 110% growth in 2025 if price increases hold. Analyst estimates for 2025 revenue have risen sharply, and Q2 expectations now exceed both company guidance and my own projections. Recent price increases for Briumvi and pipeline catalysts like a subcutaneous version could drive further outperformance versus current expectations.
TG Therapeutics, Inc. (TGTX) Q1 2025 Earnings Call Transcript
TG Therapeutics, Inc. (NASDAQ:TGTX ) Q1 2025 Earnings Conference Call May 5, 2025 8:30 AM ET Company Participants Jenna Bosco - Chief Communications Officer Michael Weiss - Chairman and Chief Executive Officer Adam Waldman - Chief Commercialization Officer Sean Power - Chief Financial Officer Conference Call Participants Tara Bancroft - TD Cowen Michael DiFiore - Evercore ISI Roger Song - Jefferies Mayank Mamtani - B. Riley Securities Prakhar Agrawal - Cantor Fitzgerald Operator Greetings, and welcome to TG Therapeutics First Quarter Conference Call and Webcast.
TG Therapeutics (TGTX) Lags Q1 Earnings Estimates
TG Therapeutics (TGTX) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.18 per share. This compares to loss of $0.07 per share a year ago.
TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why
Strong adoption of TGTX's sole marketed product, Briumvi, approved for treating relapsing forms of multiple sclerosis, is driving the top line.
These Insurance Stocks And Biotech Leader Hit New Highs As Stock Market Crumbles
Insurance stock Root soared to a new high on Friday. The IBD 50 holding has an ideal Composite and Relative Strength Rating.
Stock Of The Day: TG Therapeutics Breaks Out, May Head Higher
Trading is subdued with TG Therapeutics, Inc. TGTX on Friday. But the shares remain in an uptrend and there is a good chance the trend will continue.
Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength?
TG Therapeutics (TGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
TG Therapeutics: Bright Outlook, Bolstered By Briumvi And Upcoming Trials
TG Therapeutics is rated a strong buy with a 12-month price target of $44, driven by positive Briumvi sales and future trial plans. Briumvi exceeded FY 2024 sales forecasts and is expected to surpass the $525M goal for FY 2025, with promising patient enrollment trends. Upcoming pivotal trials and potential label updates for Briumvi, including subcutaneous administration, could enhance patient convenience and treatment efficacy.
